A Phase I Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2820151 in Subjects With Advanced or Recurrent Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 05 Apr 2018
At a glance
- Drugs GSK 2820151 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors GlaxoSmithKline
- 30 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated
- 24 Apr 2017 Planned primary completion date changed from 1 Mar 2018 to 20 May 2019.